CD4 and tuberculosis: The 2023 World Health Organization (WHO) guidelines recommend the use of the urinary lipoarabinomannan (TB‐LAM) test in patients with HIV and CD4 counts below 200 cells/μL or who are seriously ill, even if unable to produce sputum [10].